iShares Biotechnology ETF

IBB

Market cap $5.64B

Overview Fund Activity

140.72 USD

-0.26

0.18%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

140.72

0.00

0%

1 day

-0.18%

5 days

-1.39%

1 month

1.41%

3 months

10.07%

6 months

3.39%

Year to date

5.88%

1 year

-4.98%

5 years

3.42%

10 years

18.1%

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

28% more call options, than puts

Call options by funds: $216M | Put options by funds: $168M

5.24% more ownership

Funds ownership: 68.59% [Q1] → 73.84% (+5.24%) [Q2]

1% less capital invested

Capital invested by funds: $3.97B [Q1] → $3.93B (-$37.6M) [Q2]

5% less funds holding

Funds holding: 821 [Q1] → 782 (-39) [Q2]

13% less funds holding in top 10

Funds holding in top 10: 8 [Q1] → 7 (-1) [Q2]

30% less first-time investments, than exits

New positions opened: 57 | Existing positions closed: 82

60% less repeat investments, than reductions

Existing positions increased: 136 | Existing positions reduced: 342

See Fund Rankings

Financial journalist opinion

Based on 7 articles about IBB published over the past 30 days

Biotech Sector May Flip to Market Leader by Year-End

The biotech sector has been one of the market's laggards for several years now, and 2025 has been no different, at least on the surface. Year-to-date, the iShares Nasdaq Biotechnology ETF NASDAQ: IBB, which tracks the NASDAQ Biotechnology Index, is up just over 8%.

Biotech Sector May Flip to Market Leader by Year-End

Stock Market ETFs Update: This Week's Trading Ranges

This is a good time to step back and gain some perspective on the key ETFs I follow as the market anticipates several economic happenings, such as: I start with the Transportation Sector ETF (NYSEARCA: IYT) looking at the weekly chart.

Stock Market ETFs Update: This Week's Trading Ranges

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

Biotech is back – and it's playing for keeps. President Donald Trump's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments, from domestic manufacturing to cutting-edge R&D.

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

CNBC Television

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Jared Holz, Mizuho healthcare strategist, joins 'Power Lunch' to discuss the change in sentiment in the healthcare sector, the differences in the biotech ETFs and much more.

Real assets in biotech serving big markets the Street is finally noticing, says Mizuho's Jared Holz

Key Stock Market ETFs Outperforming The S&P 500

Even with Monday's correction, small caps continue to see rotation. The Russell 2000 ETF (NYSEARCA: IWM) had a topping pattern last week.

Key Stock Market ETFs Outperforming The S&P 500

BBH Vs. IBB: How To Prepare For The Next Biotech Growth Cycle With BBH

Biotech is entering a new growth cycle driven by AI and CRISPR innovation, but current ETF valuations are high and volatility is elevated. BBH offers a concentrated portfolio of leading innovators with strong cash reserves, while IBB provides broader diversification but dilutes exposure to top players. Despite optimism for sector catalysts, both BBH and IBB have underperformed historically and now trade at the upper end of their price ranges.

BBH Vs. IBB: How To Prepare For The Next Biotech Growth Cycle With BBH

Zacks Investment Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Zacks Investment Research

Should You Invest in the iShares Biotechnology ETF (IBB)?

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the iShares Biotechnology ETF (IBB), a passively managed exchange traded fund launched on February 5, 2001.

Should You Invest in the iShares Biotechnology ETF (IBB)?

Trump's deadline looms for Big Pharma companies facing new tariffs

'The Big Money Show' panel discusses President Donald Trump's pharmaceutical tariff strategy.

Trump's deadline looms for Big Pharma companies facing new tariffs

Investors Business Daily

Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn

Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month, making good on months of threats.

Donald Trump Is Finally Making Good On Pharma Tariffs Threats, But Stocks Yawn

See News Rankings

Charts implemented using Lightweight Charts™